Loading...

MedXY AI/MedXY News/Tag: obesity

MedXY News

EnglishTag

obesity

108 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

The LIMB-Q trial demonstrates that intensive lifestyle interventions combining weight management and exercise preserve bone quality in older adults with obesity, despite significant weight loss, highlighting a promising approach for mitigat

Section: Diabetes & EndocrinologyOct 7, 2025

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

Explore five scientifically supported dietary patterns that aid effective weight loss for individuals struggling with obesity, emphasizing balanced nutrition and sustainable lifestyle changes.

Section: Family Medicine & Nutrition

Oct 8, 2025

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral

A randomized clinical trial found that different timing schedules of an 8-hour time-restricted eating window combined with Mediterranean diet education did not significantly affect sleep, mood, or quality of life in adults with overweight o

Section: Clinical UpdatesOct 8, 2025

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Section: CardiologyOct 8, 2025

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Section: Clinical UpdatesOct 8, 2025

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Section: Diabetes & EndocrinologyOct 8, 2025

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Section: Clinical UpdatesOct 8, 2025

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Section: Clinical UpdatesOct 8, 2025

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

Combining aerobic and resistance exercise with diet-induced weight loss in older adults with obesity significantly improves insulin secretion, metabolic health, and physical function, likely mediated by ciliary neurotrophic factor receptor

Section: Clinical UpdatesOct 8, 2025

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul

Section: Clinical UpdatesOct 8, 2025

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Section: Clinical UpdatesOct 8, 2025

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Section: CardiologyOct 8, 2025

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerabi

Section: Diabetes & EndocrinologyOct 7, 2025

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Section: Diabetes & EndocrinologyOct 7, 2025

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

Section: Clinical UpdatesOct 7, 2025

The Hidden Battle in Our Brain: Why We Can’t Resist Hedonic Eating

The Hidden Battle in Our Brain: Why We Can’t Resist Hedonic Eating

Discover how dopamine neurons in the brain’s reward center overpower satiety signals, driving hedonic eating even when we’re full, revealing new insights for obesity treatment.

Section: Family Medicine & NutritionOct 6, 2025

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety an

Section: Clinical UpdatesAug 31, 2025

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assess

Section: CardiologyOct 6, 2025

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.

Section: Diabetes & EndocrinologyOct 6, 2025

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.

Section: Diabetes & EndocrinologyOct 6, 2025

Prev 1 2 3 4 5 6 Next